Occurrence of Spike Antigen Specific SARS-CoV-2 Antibodies in Pre-Pandemic Samples of Domestic Cats Raises New Questions

Lebedin, Y.; Petukhov, P.; Maygurova, V.; Klyuchnikova, Polina S.; Найденко, С. В.

doi:10.1134/s1062359021150103

Cited by 1 publication

(1 citation statement)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study of antibodies to SARS‐CoV‐2 in sera of domestic cats post‐pandemic in Moscow in 2020 showed 10% were positive for IgG against SARS‐CoV‐2 RBD and five pre‐pandemic Moscow cat sera from 2018 (2.9% of 172 cat sera assessed) were also IgG‐positive for SARS‐CoV‐2 RBD; conversely, no pre‐pandemic domestic cat samples from the Russian Far East were seropositive (Lebedin et al., 2021). There was no relationship between SARS‐CoV‐2 and FCoV seropositivity suggesting FCoV cross reactivity was not the explanation for the SARS‐CoV‐2 reactive pre‐pandemic cat sera.…”

Section: Discussionmentioning

confidence: 99%

Safety and immunogenicity of an adjuvanted recombinant spike protein‐based severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccine, SpikeVet™, in selected Carnivora, Primates and Artiodactyla in Australian zoos

McLelland,

Lynch,

Vogelnest

et al. 2024

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) can infect a broad range of animal species and has been associated with severe disease in some taxa. Few studies have evaluated optimal strategies to mitigate the risk to susceptible zoo animals. This study evaluated the safety and immunogenicity of a protein‐based veterinary SARS‐CoV‐2 vaccine (SpikeVet™) in zoo animals. Two to three doses of SpikeVet™ were administered intramuscularly or subcutaneously 3–4 weeks apart to 354 zoo animals representing 38 species. SpikeVet™ was very well tolerated across all species. Minor adverse effects were observed in 1.69% of animals vaccinated, or 1.04% of vaccine doses administered. Preliminary immunogenicity analyses in representative carnivores (meerkats, lions) and an artiodactylid (domestic goat) showed SpikeVet™‐immunized animals developed serum antibodies able to neutralize a range of SARS‐CoV‐2 variants, including the vaccine‐homologous Wuhan and Mu variants, as well as vaccine‐heterologous Omicron BA.2 and XBB.1 strains. Prior to vaccination, all eight lions were seropositive for Wuhan strain by surrogate viral neutralization testing, suggesting past infection with SARS‐CoV‐2 or cross‐reactive antibodies generated by another closely related coronavirus. These results from a range of zoo species support the ongoing development of SpikeVet™ as a safe and effective veterinary SARS‐CoV‐2 vaccine.

show abstract

Section: Discussionmentioning

confidence: 99%